Neoantigen vaccine: an emerging tumor immunotherapy
2019 · Molecular Cancer · 688 citations
https://doi.org/10.1186/s12943-019-1055-6
X
Xiaoling Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
416
Papers
10.4K
Citations
54
h-index
150
i10-index
Xiaoling Li is an academic researcher from Jiangnan University. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Epigenetics and DNA Methylation & Lung Cancer Treatments and Mutations. The author has an h-index of 54, co-authored 354 publications.
ORCID: 0000-0002-1554-1569Papers by this author
worksCircular RNAs in human cancer
2017 · Molecular Cancer · 524 citations
https://doi.org/10.1186/s12943-017-0598-7
Natural killer group 2D receptor and its ligands in cancer immune escape
2019 · Molecular Cancer · 233 citations
https://doi.org/10.1186/s12943-019-0956-8
Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance
2022 · Nature Cancer · 143 citations
https://doi.org/10.1038/s43018-022-00431-9
Fibronectin-Tissue Transglutaminase Matrix Rescues RGD-impaired Cell Adhesion through Syndecan-4 and β1 Integrin Co-signaling
2008 · Journal of Biological Chemistry · 128 citations
https://doi.org/10.1074/jbc.m801763200
Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells
2021 · Biomedicine & Pharmacotherapy · 104 citations
https://doi.org/10.1016/j.biopha.2021.112515
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat